Certainly can't hurt but totally agreed. SAEs may not have been fully reported by Novartis but gleevac has been used as the control arm in numerous studies. The safety profile still exceeds it's competition even reported by competitor studies. While it might not be good for Novartis from a legal perspective it doesn't translate to a windfall far ariad.
News 
Market Data 
Discover 
